SHERIDAN, WYOMING - May 13, 2026 - TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy, has confirmed that President and Chief Executive Officer James A. Bianco, M.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City on May 19, 2026, at 2:00 pm ET. The appearance gives institutional investors and sector analysts direct access to leadership at a moment when TuHURA is running an active Phase 3 registration trial and advancing two additional pipeline programs. For stakeholders tracking immuno-oncology development timelines and clinical positioning, the session represents a structured opportunity to assess the company's near-term milestones.
A Pipeline Built Around Immunotherapy Resistance
The core clinical problem TuHURA is addressing is not rare. Primary and acquired resistance to cancer immunotherapy are among the most common reasons checkpoint inhibitors fail - either by never producing a response or by losing efficacy over time in the majority of patients with cancer. TuHURA's pipeline is built entirely around this failure mode, targeting the biological mechanisms that allow tumors to evade or exhaust immune responses.
This focus shapes all three of the company's current development programs. Each addresses a distinct point in the resistance pathway - from initial non-response to acquired treatment failure - positioning TuHURA as a platform-driven immuno-oncology developer rather than a single-asset clinical-stage company.
IFx-2.0 Phase 3 Trial: Adjunctive Therapy for Merkel Cell Carcinoma
TuHURA's lead candidate, IFx-2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized, placebo-controlled Phase 3 registration trial evaluating IFx-2.0 as an adjunctive therapy to pembrolizumab (Keytruda®) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
The trial compares Keytruda® plus IFx-2.0 against Keytruda® plus placebo. For clinical development professionals and oncology-focused investors, the single-trial registration design carries meaningful regulatory implications - a successful outcome would position IFx-2.0 directly on a commercialization pathway without the need for additional confirmatory studies. Merkel Cell Carcinoma, while relatively rare, is an aggressive malignancy where first-line checkpoint inhibitor performance is a clinically significant unmet need.
TBS2025 Advances into Phase 1b/2 in Molecularly Defined AML
Alongside its lead program, TuHURA is developing TBS2025, a monoclonal antibody targeting VISTA, a checkpoint pathway distinct from PD-1 and CTLA-4. TBS2025 is moving into Phase 1b/2 clinical evaluation in mutNPM1 relapsed or refractory Acute Myeloid Leukemia - a molecularly defined patient subgroup within AML.
The precision of this target population matters operationally. By selecting a genetically characterized subgroup, TuHURA reduces clinical heterogeneity and sharpens the signal-to-noise ratio in early-phase data. For investors evaluating pipeline risk, this approach reflects a disciplined development strategy rather than broad exploratory positioning.
Delta Opioid Receptor Technology Targets Acquired Resistance
The third program applies TuHURA's Delta Opioid Receptor technology to develop first-in-class bi-specific, bi-functional antibody-drug conjugates targeting Myeloid-Derived Suppressor Cells. MDSCs are a key driver of the immunosuppressive tumor microenvironment - their activity contributes directly to T-cell exhaustion and acquired resistance to both checkpoint inhibitors and cellular therapies.
By targeting MDSCs at the tumor microenvironment level, TuHURA is addressing acquired resistance from a mechanistic angle that differs from most current checkpoint inhibitor combinations. The bi-specific, bi-functional ADC format is designed to combine targeting precision with direct suppressor cell inhibition - a structural approach intended to maintain durable immune responses over the treatment course.
Conference Access and Webcast Details
The fireside chat with Dr. Bianco is scheduled for Tuesday, May 19, 2026, at 2:00 pm ET. A live and archived webcast of the presentation will be available through TuHURA's investor relations portal. The archived format ensures that stakeholders unable to attend live retain access to the full session for subsequent review.